Orphan Drug Designation granted to Benitec Biopharma By: MarketMinute.com Stock News January 17, 2017 at 16:34 PM EST The European Commission granted Orphan Drug Designation to Benitec Biopharma Ltd.'s (Nasdaq: BNTC) oculopharyngeal muscular dystrophy treatment BB-301 sending the stock price soaring $1.15 to close at $3.00. Related Stocks: Benitec Biopharma Ltd ADR